The record
Written from the 1 report below. Nothing here is unsourced.
- The Dadachanji group has returned to pharmaceutical glass packaging by launching Kaisha Pharma, five years after selling its stake in the Schott Kaisha joint-venture to Serum Institute of India in 2021.
- The group has put in an initial €45 million investment and plans a more global approach than its earlier India-focused operations.
- Kaisha Pharma will offer tubular glass products such as ampoules, vials, prefilled syringes and cartridges, along with ready-to-use platforms for fill-finish operations.
- A manufacturing complex of over 300,000 square feet is planned, and an international business development office is being set up in Europe.
What to watch next
- Progress of the €45 million investment and ramp-up of the manufacturing complex
- Launch and operations of the European business development office
- How Kaisha Pharma's specialty containment solutions for biologics and advanced therapeutics develop
Who said what1
Only words found exactly in the article are shown, attributed and linked to the line they came from.
Kairus Dadachanji
1 quote · 1 outlet
“Our previous experience was a defining chapter in our professional journey”
In the article
…developing a range of specialty containment solutions for high-value biologics, advanced therapeutics, and sensitive drug formulations, where product integrity, compatibility, and performance are critical,” it said. “ Our previous experience was a defining chapter in our professional journey ,” said Kairus Dadachanji, Managing Director of Kaisha Pharma, adding that the plan now was to create a global company that combined entrepreneurial agility with technical excellence. The company is also setting up an…
Coverage1
All filed from India
Named India · Schott Kaisha · Serum Institute of India · Dadachanji group · Kairus Dadachanji · Kaisha Pharma
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.